Table I.
Study group characteristics.
| Group data | ||
|---|---|---|
| Feature | n | % |
| Total patients studied | 52 | 100.0 |
| Tumor size | ||
| T1 | 31 | 59.6 |
| T2 | 17 | 32.7 |
| T3 | 4 | 7.7 |
| Metastasis | ||
| M0 | 43 | 82.7 |
| M1 | 1 | 1.9 |
| Mx | 8 | 15.4 |
| Lymph nodes | ||
| N0 | 13 | 25.0 |
| N1 | 30 | 57.7 |
| N2 | 0 | 0.0 |
| N3 | 1 | 1.9 |
| Nx | 8 | 15.4 |
| Histological grade | ||
| G1 | 13 | 25.0 |
| G2 | 23 | 44.2 |
| G3 | 13 | 25.0 |
| Gx | 3 | 5.8 |
| ER status | ||
| ER+ | 45 | 86.5 |
| ER− | 7 | 13.5 |
| PgR status | ||
| PgR+ | 39 | 75.0 |
| PgR− | 13 | 25.0 |
| HER2 status | ||
| HER2+ | 26 | 50.0 |
| HER2− | 26 | 50.0 |
Tumors were characterized according to histological grade, tumor size, lymph node and receptor status (ER, PgR and HER2). ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor 2.